Related Experiment Video

Updated: May 21, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates?

Anne Smits1, Roosmarijn F W De Cock, Veerle Cossey

  • 1Neonatal intensive care unit, University Hospitals Leuven, Belgium. anne.smits@uzleuven.be

Biomarkers in Medicine
|June 27, 2012
PubMed

Insights

Neonatal propofol clearance varies significantly between infants. Postmenstrual age (PMA) and postnatal age (PNA) are better predictors of propofol clearance than indirect bilirubin levels.

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Pharmacokinetics

Background:

  • Significant interindividual variability exists in neonatal propofol clearance.
  • Postmenstrual age (PMA) and postnatal age (PNA) partially explain this variability.

Purpose of the Study:

  • To investigate if indirect bilirubin improves the prediction of propofol clearance in neonates.
  • To assess indirect bilirubin as a potential biomarker for reduced propofol clearance.

Main Methods:

  • A three-compartment pharmacokinetic model was utilized.
  • Indirect serum bilirubin was incorporated as a covariate (dichotomous or continuous).
  • Nonlinear mixed-effects modeling (NLME 6.2) was applied to 235 concentration-time points from 25 neonates.

Main Results:

  • The model including PMA and PNA explained 67% of interindividual variability in propofol clearance.
  • A model incorporating PMA and bilirubin explained only 45% of the variability.

Conclusions:

  • Postmenstrual age (PMA) and postnatal age (PNA) are more significant clinical predictors of neonatal propofol clearance.
  • Indirect hyperbilirubinemia is a less relevant predictor compared to age-related factors.
Abstract

More Related Videos

Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics in Infants11:39

Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics in Infants

Published on: March 14, 2013

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.